If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2019

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

Weisel, K., Sonneveld, P., Spencer, A., Beksac, M., Rizzo, M., Xu, Y., Fahrbach, K., Gaudig, M., Slavcev, M., Dearden, L. & Lam, A., 1 Jan 2019, In : Leukemia and Lymphoma. 60, 19, p. 151–162 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
1 Citation (Scopus)

DNA-repair gene mutations are highly prevalent in circulating tumour dna from multiple myeloma patients

Mithraprabhu, S., Hocking, J., Ramachandran, M., Choi, K., Klarica, D., Khong, T., Reynolds, J. & Spencer, A., 29 Jun 2019, In : Cancers. 11, 7, 14 p., 917.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling

Liu, H., Hu, Y., Rimoldi, R., Von Hagt, C., Khong, E. W. C., Lee, N., Flemming, S., Spencer, A. & Dear, A. E., Feb 2019, In : Oncology Letters. 17, 2, p. 2543-2550 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
2 Citations (Scopus)

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients

Mithraprabhu, S., Morley, R., Khong, T., Kalff, A., Bergin, K., Hocking, J., Savvidou, I., Bowen, K. M., Ramachandran, M., Choi, K., Wong, B. K. L., Reynolds, J. & Spencer, A., Aug 2019, In : Leukemia. 33, 8, p. 2022-2033 12 p.

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)

Kalff, A., Khong, T., Mithraprabhu, S., Bergin, K., Reynolds, J., Bowen, K. M., Thakurta, A., Guzman, R., Wang, M., Couto, S., Ren, Y. & Spencer, A., 29 Jul 2019, In : Leukemia and Lymphoma. 60, 9, p. 2143-2151 9 p.

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

Kumar, S. K., Grzasko, N., Delimpasi, S., Jedrzejczak, W. W., Grosicki, S., Kyrtsonis, M. C., Spencer, A., Gupta, N., Teng, Z., Byrne, C., Labotka, R. & Dimopoulos, M. A., 1 Feb 2019, In : British Journal of Haematology. 184, 4, p. 536-546 11 p.

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related Diseases Registry

Ho, P. J., Moore, E. M., McQuilten, Z. K., Wellard, C., Bergin, K., Augustson, B., Blacklock, H., Harrison, S. J., Horvath, N., King, T., Mollee, P., Quach, H., Reid, C., Rosengarten, B., Walker, P., Wood, E. M. & Spencer, A., Aug 2019, In : Clinical Lymphoma, Myeloma and Leukemia. 19, 8, p. E415-E424 10 p.

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Utility of circulating cell-free RNA analysis for the characterization of global transcriptome profiles of multiple myeloma patients

Chen, M., Mithraprabhu, S., Ramachandran, M., Choi, K., Khong, T. & Spencer, A., 1 Jun 2019, In : Cancers. 11, 6, 19 p., 887.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
1 Citation (Scopus)
2018

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results

Spencer, A., Harrison, S., Zonder, J., Badros, A., Laubach, J., Bergin, K., Khot, A., Zimmerman, T., Chauhan, D., Levin, N., MacLaren, A., Reich, S. D., Trikha, M. & Richardson, P., 1 Jan 2018, In : British Journal of Haematology. 180, 1, p. 41-51 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
26 Citations (Scopus)

Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

Goldschmidt, H., Moreau, P., Ludwig, H., Niesvizky, R., Chng, W. J., Joshua, D., Weisel, K., Spencer, A., Orlowski, R. Z., Feng, S., Iskander, K. S. & Dimopoulos, M. A., 2018, In : Leukemia and Lymphoma. 59, 6, p. 1364-1374 11 p.

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)
7 Citations (Scopus)

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Quach, H., Benson, S., Haysom, H., Wilkes, A. M., Zacher, N., Cole-Sinclair, M., Miles Prince, H., Mollee, P., Spencer, A., Joy Ho, P., Harrison, S. J., Lee, C., Augustson, B. & Daly, J., 1 Feb 2018, In : Internal Medicine Journal. 48, 2, p. 210-220 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
7 Citations (Scopus)

Contemporary analysis of functional immune recovery to opportunistic and vaccine-preventable infections after allogeneic haemopoietic stem cell transplantation

De Silva, H., Ffrench, R. A., Korem, M., Orlowski-Oliver, E., Curtis, D. J., Spencer, A., Avery, S., Patil, S. & Morrissey, C. O., 1 Jan 2018, In : Clinical & Translational Immunology. 7, 10, 16 p., e1040.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

Spencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M. D., Bosi, A., Hungria, V., Cavo, M., Lee, J. J., Nooka, A. K., Quach, H., Lee, C., Barreto, W., Corradini, P., Min, C. K., Scott, E. C. & 17 others, Chanan-Khan, A. A., Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J. C., Shin, H. J., Sonneveld, P., Soong, D., Casneuf, T., Chiu, C., Amin, H., Qi, M., Thiyagarajah, P., Sasser, A. K., Schecter, J. M. & Mateos, M. V., 30 Nov 2018, In : Haematologica: the hematology journal. 103, 12, p. 2079-2087 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
67 Citations (Scopus)

DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma

Yuen, H. L. A., Low, M. S. Y., Fedele, P., Kalff, A., Walker, P., Bergin, K., Coutsouvelis, J., Grigoriadis, G. & Spencer, A., 2 Dec 2018, In : Leukemia and Lymphoma. 59, 12, p. 2842-2846 5 p.

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Defibrotide for the treatment of sinusoidal obstruction syndrome: evaluation of response to therapy and patient outcomes

Coutsouvelis, J., Avery, S., Dooley, M., Kirkpatrick, C. & Spencer, A., 1 Mar 2018, In : Supportive Care in Cancer. 26, 3, p. 947-955 9 p.

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study

Gopal, A. K., Schuster, S. J., Fowler, N. H., Trotman, J., Hess, G., Hou, J. Z., Yacoub, A., Lill, M., Martin, P., Vitolo, U., Spencer, A., Radford, J., Jurczak, W., Morton, J., Caballero, D., Deshpande, S., Gartenberg, G. J., Wang, S. S., Damle, R. N., Schaffer, M. & 4 others, Balasubramanian, S., Vermeulen, J., Cheson, B. D. & Salles, G., 10 Aug 2018, In : Journal of Clinical Oncology. 36, 23, p. 2405-2412 8 p.

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)

Mining the plasma cell transcriptome for novel cell surface proteins

Trezise, S., Karnowski, A., Fedele, P. L., Mithraprabhu, S., Liao, Y., D’costa, K., Kueh, A. J., Hardy, M. P., Owczarek, C. M., Herold, M. J., Spencer, A., Shi, W., Willis, S. N., Nutt, S. L. & Corcoran, L. M., 1 Aug 2018, In : International Journal of Molecular Sciences. 19, 8, 2161.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
2 Citations (Scopus)

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response

Mina, R., Petrucci, M. T., Corradini, P., Spada, S., Patriarca, F., Cerrato, C., De Paoli, L., Pescosta, N., Ria, R., Malfitano, A., Musto, P., Baldini, L., Guglielmelli, T., Gamberi, B., Mannina, D., Benevolo, G., Zambello, R., Falcone, A. P., Palumbo, A., Nagler, A. & 5 others, Calafiore, V., Hájek, R., Spencer, A., Boccadoro, M. & Bringhen, S., 1 Aug 2018, In : Clinical Lymphoma, Myeloma & Leukemia. 18, 8, p. 533-540 8 p.

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)
2017

Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma

Nair, A. P., Walker, P., Kalff, A., Bergin, K., Hocking, J., Avery, S., Curtis, D. J., Patil, S., Das, T., Klarica, D., Morgan, S., Muirhead, J., Gorniak, M. B., Reynolds, J. & Spencer, A., 1 Jun 2017, In : Bone Marrow Transplantation. 52, 6, p. 839-845 7 p.

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis

Gay, F., Oliva, S., Petrucci, M. T., Montefusco, V., Conticello, C., Musto, P., Catalano, L., Evangelista, A., Spada, S., Campbell, P., Ria, R., Salvini, M., Offidani, M., Carella, A-M., Omedé, P., Liberati, A. M., Troia, R., Cafro, A. M., Malfitano, A., Falcone, A. P. & 7 others, Caravita, T., Patriarca, F., Nagler, A., Spencer, A., Hajek, A. R., Palumbo, A. & Boccadoro, M., 1 Aug 2017, In : Leukemia. 31, 8, p. 1727-1734 8 p.

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., Traunbauer, A. K., Sadovnik, I., Bauer, K., Valent, P., Bradner, J. E., Zuber, J., Shortt, J. & Johnstone, R. W., 28 Feb 2017, In : Cell Reports. 18, 9, p. 2162-2174 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
88 Citations (Scopus)

Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma

Mithraprabhu, S., Khong, T., Ramachandran, M., Chow, A., Klarica, D., Mai, L., Walsh, S., Broemeling, D., Marziali, A., Wiggin, M., Hocking, J., Kalff, A., Durie, B. & Spencer, A., 1 Aug 2017, In : Leukemia. 31, 8, p. 1695-1705 11 p.

Research output: Contribution to journalArticleResearchpeer-review

43 Citations (Scopus)

Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation

Yong, M. K., Cameron, P. U., Slavin, M., Morrissey, C. O., Bergin, K., Spencer, A., Ritchie, D., Cheng, A. C., Samri, A., Carcelain, G., Autran, B. & Lewin, S. R., 1 Jun 2017, In : Journal of Infectious Diseases. 215, 11, p. 1684-1694 11 p.

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)

Low T-cell responses to mitogen stimulation predicts poor survival in recipients of allogeneic hematopoietic stem cell transplantation

Yong, M. K., Cameron, P. U., Slavin, M. A., Cheng, A. C., Orla Morrissey, C., Bergin, K., Spencer, A., Ritchie, D. & Lewin, S. R., 9 Nov 2017, In : Frontiers in Immunology. 8, NOV, 9 p., 1506.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
4 Citations (Scopus)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

Kumar, S. K., Moreau, P., Hari, P., Mateos, M-V., Ludwig, H., Shustik, C., Masszi, T., Spencer, A., Hájek, R., Romeril, K., Avivi, I., Liberati, A. M., Minnema, M. C., Einsele, H., Lonial, S., Berg, D., Lin, J., Gupta, N., Esseltine, D-L. & Richardson, P. G., Aug 2017, In : British Journal of Haematology. 178, 4, p. 571-582 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
30 Citations (Scopus)

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study

Quach, H., White, D., Spencer, A., Ho, P. J., Bhutani, D., White, M., Inamdar, S., Morris, C., Ou, Y. & Gyger, M., Jun 2017, In : Cancer Chemotherapy and Pharmacology. 79, 6, p. 1067-1076 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
10 Citations (Scopus)

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study

Tan, P., Tiong, I. S., Fleming, S., Pomilio, G., Cummings, N., Droogleever, M., McManus, J., Schwarer, A., Catalano, J., Patil, S., Avery, S., Spencer, A. & Wei, A., 2017, In : Oncotarget. 8, 32, p. 52269-52280 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Talaulikar, D., Tam, C. S., Joshua, D. E., Ho, P. J., Szer, J., Quach, H., Spencer, A., Harrison, S. J., Mollee, P., Roberts, A. W., Horvath, N., Lee, C., Zannettino, A. C. W., Brown, R. D., Augustson, B. M., Jaksic, W. J., Gibson, J., Kalff, A., Johnston, A., Trotman, J. & 4 others, Kalro, A., Grigoriadis, G., Ward, C. & Prince, H. M., 1 Jan 2017, In : Internal Medicine Journal. 47, 1, p. 35-49 15 p.

Research output: Contribution to journalArticleOtherpeer-review

7 Citations (Scopus)

β-catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma

Savvidou, I., Khong, T., Cuddihy, A., McLean, C., Horrigan, S. & Spencer, A., 1 Sep 2017, In : Molecular Cancer Therapeutics. 16, 9, p. 1765-1778 14 p.

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)
2016

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D. E., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K. C., Goranova-Marinova, V., Schwarer, A. & 11 others, Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S. & Chng, W. J., 1 Jan 2016, In : The Lancet Oncology. 17, 1, p. 27-38 12 p.

Research output: Contribution to journalArticleResearchpeer-review

404 Citations (Scopus)

Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents

Lipton, A., Smith, M. R., Fizazi, K., Stopeck, A. T., Henry, D. A., Brown, J. E., Shore, N. D., Saad, F., Spencer, A., Zhu, L. & Warner, D. J., 1 Dec 2016, In : Clinical Cancer Research. 22, 23, p. 5713-5721 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
14 Citations (Scopus)

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K. C., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M-V., Mark, T. M., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Spencer, A. & Sonneveld, P., 25 Aug 2016, In : The New England Journal of Medicine. 375, 8, p. 754-766 13 p.

Research output: Contribution to journalArticleResearchpeer-review

581 Citations (Scopus)

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry

Bergin, K., Moore, E., McQuilten, Z., Wood, E., Augustson, B., Blacklock, H., Ho, J., Horvath, N., King, T., McNeil, J., Mollee, P., Quach, H., Reid, C. M., Rosengarten, B., Walker, P. & Spencer, A., 9 Nov 2016, In : BMC Medical Research Methodology. 16, 1, 8 p., 151.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
7 Citations (Scopus)

Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies

Liu, H. B., Pattie, P., Chandrasekara, S., Spencer, A. & Dear, A. E., Sep 2016, In : Oncology Letters. 12, 3, p. 2175-2180 6 p.

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

Raje, N., Vadhan-Raj, S., Willenbacher, W., Terpos, E., Hungria, V., Spencer, A., Alexeeva, Y., Facon, T., Stewart, A. K., Feng, A., Braun, A., Balakumaran, A. & Roodman, G. D., 8 Jan 2016, In : Blood Cancer Journal. 6, 5 p., e378.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
35 Citations (Scopus)

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, H. J., Suvorov, A. N., Xiu, L., Cakana, A., Parekh, T. & San-Miguel, J. F., 1 Jul 2016, In : Cancer. 122, 13, p. 2050-2056 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
27 Citations (Scopus)

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: Pivotal role of MCL1

Gong, J. N., Khong, T., Segal, D., Yao, Y., Riffkin, C. D., Garnier, J. M., Lin Khaw, S., Lessene, G., Spencer, A., Herold, M. J., Roberts, A. W. & Huang, D. C. S., 1 Jan 2016, In : Blood. 128, 14, p. 1834-1844 11 p.

Research output: Contribution to journalArticleResearchpeer-review

60 Citations (Scopus)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients

Levin, N., Spencer, A., Harrison, S. J., Chauhan, D., Burrows, F. J., Anderson, K. C., Reich, S. D., Richardson, P. G. & Trikha, M., 1 Sep 2016, In : British Journal of Haematology. 174, 5, p. 711-720 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
19 Citations (Scopus)

Mitochondrial DNA plasticity is an essential inducer of tumorigenesis

Lee, WTY., Cain, JE., Cuddihy, AR., Johnson, J., Dickinson, A., Yeung, K-Y., Kumar, B., Johns, TG., Watkins, DN., Spencer, A. & St John, JC., 2016, In : Cell Death Discovery. 2, p. 1 - 11 11 p., 16016.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
14 Citations (Scopus)

Phase i clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: Study NPI-0052-102 final results

Harrison, S. J., Mainwaring, P., Price, T., Millward, M. J., Padrik, P., Underhill, C. R., Cannell, P. K., Reich, S. D., Trikha, M. & Spencer, A., 15 Sep 2016, In : Clinical Cancer Research. 22, 18, p. 4559-4566 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
32 Citations (Scopus)

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: A multicentre audit

Doan, T. N., Kirkpatrick, C. M. J., Walker, P., Slavin, M. A., Ananda-Rajah, M. R., Morrissey, C. O., Urbancic, K. F., Grigg, A. P., Spencer, A., Szer, J., Seymour, J. F. & Kong, D. C. M., 1 Feb 2016, In : Journal of Antimicrobial Chemotherapy. 71, 2, p. 497-505 9 p., dkv343.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
19 Citations (Scopus)
2015

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial

Gay, F., Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., Siniscalchi, A., Magarotto, V., Pour, L., Carella, A-M., Malfitano, A., Petrò, D., Evangelista, A., Spada, S., Pescosta, N., Omedè, P., Campbell, P., Liberati, A. M., Offidani, M., Ria, R. & 6 others, Pulini, S., Patriarca, F., Hajek, R., Spencer, A., Boccadoro, M. & Palumbo, A., 2015, In : The Lancet Oncology. 16, 16, p. 1617-1629 13 p.

Research output: Contribution to journalArticleResearchpeer-review

164 Citations (Scopus)

Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation

Pham, T., Patil, S., Fleming, S. A., Avery, S., Walker, P. A., Wei, A., Curtis, D. J., Stuart, G., Klarica, D., O'Brien, M., Morris, K., Das, T. P., Bollard, G. M., Muirhead, J., Coutsouvelis, J. & Spencer, A., 2015, In : Transfusion. 55, 11, p. 2709 - 2713 5 p.

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

Dimopoulos, M. A., Weisel, K. C., Song, K. W., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Banos, A., Oriol, A., Garderet, L., Cavo, M. M., Ivanova, V., Alegre, A., Martinez-Lopez, J., Chen, C., Spencer, A., Knop, S., Bahlis, N. J., Renner, C., Yu, X. & 5 others, Hong, K., Sternas, L., Jacques, C., Zaki, M. & San Miguel, J. F., 2015, In : Haematologica: the hematology journal. 100, 10, p. 1327 - 1333 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
53 Citations (Scopus)

Elotuzumab therapy for relapsed or refractory multiple myeloma

Lonial, S., Dimopoulos, M. A., Palumbo, A., White, D. J., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M-V., Magen, H., Belch, A. R., Reece, D. E., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Rollig, C., Einsele, H., Wu, K. L. & 8 others, Singhal, A., San Miguel, J. F., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K. C. & Richardson, P. G., 2015, In : The New England Journal of Medicine. 373, 7, p. 621 - 631 11 p.

Research output: Contribution to journalArticleResearchpeer-review

676 Citations (Scopus)

Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia

Wei, A., Tan, P. T. G., Perruzza, S. N., Govindaraj, C., Fleming, S. A., McManus, J. F., Avery, S., Patil, S., Stevenson, W. C., Plebanski, M. & Spencer, A., 2015, In : British Journal of Haematology. 169, 2, p. 199 - 210 12 p.

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide

Asvadi, P., Cuddihy, A. R., Dunn, R., Jiang, V., Wong, M. X., Jones, D. R., Khong, T. T. F. & Spencer, A., 2015, In : British Journal of Haematology. 169, 3, p. 333 - 343 11 p.

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease

Bortz, H. D., Coutsouvelis, J., Corallo, C., Spencer, A. & Patil, S., 2015, In : Journal of Clinical Pharmacy and Therapeutics. 40, 4, p. 483 - 485 3 p.

Research output: Contribution to journalArticleOther